Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

2-arylaminopyrimidine derivatives containing hydroxamic acid fragments and their preparation and application

An arylaminopyrimidine and hydroxamic acid technology, which is applied in the field of 2-arylaminopyrimidine derivatives, can solve the problems of poor proliferation inhibition selectivity, adverse drug reactions and the like, and achieves good inhibition effect.

Inactive Publication Date: 2018-05-08
ZHEJIANG UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Effect of second-generation irreversible EGFR inhibitors on human epidermal carcinoma cells A431 with high expression of EGFR WT,overexpression , Gefitinib-resistant human non-small cell lung cancer cell line H1975 L858R / T790M Proliferation inhibition between
However, the combination of drugs may cause adverse drug reactions due to drug interactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 2-arylaminopyrimidine derivatives containing hydroxamic acid fragments and their preparation and application
  • 2-arylaminopyrimidine derivatives containing hydroxamic acid fragments and their preparation and application
  • 2-arylaminopyrimidine derivatives containing hydroxamic acid fragments and their preparation and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 N 1 -2-fluoro-5-((4-(1-methyl-1H-indol-3-yl)-pyrimidin-2-yl)amino)phenyl)-N 4 -Hydroxymaleamide hydrochloride (compound 1)

[0036]

[0037] Reagents and reaction conditions: 1) dichloromethane, room temperature, 3-5 hours; 2) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 1-hydroxybenzotri Azole, dichloromethane:N,N-dimethylformamide=2:1, 45°C, 5 hours; 3) 1M hydrochloric acid ether solution, 30 minutes.

[0038] Step 1: (Z)-4-((2-fluoro-5-((4-(N-methyl-3-indolyl)-2-pyrimidine)amino)phenyl)amino)-4-oxo - Preparation of 2-butenoic acid Raw material 1: 2-(4-fluoro-3-aminophenyl)-4-(N-methylindole)-2-aminopyrimidine According to J.Med.Chem.2014,57 , prepared by the method of 8249-8267.

[0039] Dissolve 2-(4-fluoro-3-aminophenyl)-4-(N-methylindole)-2-aminopyrimidine (1mmol) and maleic anhydride (1.2mmol) in 15mL dichloroethane , react for 3-5 hours. After the reaction, spin dry under reduced pressure. Recrystallization from acetone gives ...

Embodiment 2

[0048] Example 2 N 1 -5-((4-(1-methyl-1H-indol-3-yl)-pyrimidin-2-yl)amino)phenyl)-N 4 -Hydroxymaleamide hydrochloride

[0049] Its structural formula is:

[0050]

[0051]Yellow solid; m.p.:181.0-181.4℃; 1 HNMR(500MHz,DMSO-d6)δ11.73(s,1H),10.98(s,1H),10.36(s,1H),8.85(s,1H),8.30(d,J=6.6Hz,2H), 8.07(s,1H),7.61(d,J=8.3Hz,1H),7.51(d,J=8.0Hz,1H),7.48–7.45(m,2H),7.39–7.23(m,3H),7.17 (t, J=7.4Hz, 1H), 6.38(d, J=12.1Hz, 1H), 6.24(d, J=12.1Hz, 1H), 3.93(s, 3H).

[0052] 13 CNMR (125MHz, DMSO-d6) δ169.1, 167.0, 158.1, 157.6, 157.3, 156.4, 137.1, 136.6, 135.3, 135.2, 131.9, 130.0, 126.5, 123.3, 122.7, 121.2, 116.0, 115.42, 100.1, 115 33.2. HRMS(ESI)calcd.for C 23 h 21 N 6 o 3 [M+H] + =429.1670, found 429.1670.

Embodiment 3

[0053] Example 3 N 1 -(2-(Dimethylamino)-5-((4-(1-methyl-1H-indol-3-yl)-pyrimidin-2-yl)amino)phenyl)-N 4 -Hydroxymaleamide hydrochloride

[0054] Its structural formula is:

[0055]

[0056] Yellow solid; m.p.:217.9–218.3℃; 1 H NMR (500MHz, DMSO-d6) δ10.31 (s, 3H), 7.65 (d, J = 7.8Hz, 1H), 7.47–7.39 (m, 6H), 7.24–7.18 (m, 3H), 6.99 ( s,1H),6.78(d,J=12.1Hz,1H),6.28(d,J=12.1Hz,1H),3.81(s,3H),3.80(s,1H),2.08–2.01(m,6H ),1.91(s,1H).HRMS(ESI)calcd.for C 25 h 26 N 7 o 3 [M+H] + = 472.2092, found 472.2095.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides 2-arylamine pyrimidine derivatives containing hydroxamic acid fragments shown in the formulas I and II. 2-arylamine pyrimidine containing carboxyl fragments is mainly used as a parent nucleus and is subjected to single-step condensation and related modification with hydroxylamine protected by THP to obtain a target compound. An experiment proves that the derivatives has the remarkable anti-proliferative effect on tumor cells (an overexpression EGFR human epidermal carcinoma cell line A431 and a human pulmonary carcinoma cell line H1975 resisting Gefitinib) related to EGFR tyrosine kinase activity on the cellular level, and tumor cells (a human cervical carcinoma cell line Hela, a human hepatoma cell line HepG2, a human promyelocytic acute leukemia cell line HL60, a human oral epidermoid carcinoma cell line KB, a human colon cancer cell line SW620) related to the HDAC histone acetylase activity, and the corresponding medicine for resisting cancer cells can be prepared. The general structural formula is shown in the description.

Description

technical field [0001] The invention belongs to the field of pharmacy, and specifically relates to a 2-arylaminopyrimidine derivative containing a hydroxamic acid segment, a preparation method, an intermediate, and an application thereof. Background technique [0002] Protein tyrosine kinases play an important role in the signal transduction process and participate in the regulation of biological processes such as cell growth, proliferation and apoptosis. Its abnormal expression can lead to cell dysfunction. Epidermal growth factor receptor (EGFR) is a typical receptor with tyrosine kinase activity and a member of the epidermal growth factor (ErbB / HER) family. Current studies have shown that overexpression or mutation of EGFR exists in various solid tumors such as lung cancer, glioblastoma (brain tumor), breast cancer, colorectal cancer, gastric cancer, head and neck cancer, and pancreatic cancer. EGFR overexpression can enhance the signal of downstream signaling pathways....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D403/04A61P35/00A61P35/02
CPCC07D403/04
Inventor 俞永平罗婧陈文腾刘星雨舒可
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com